Elaine Cloutman-Green HSS Application 1

Structured Curriculum Vitae 2

3

Career Summary 4

5

I have worked as a Healthcare Scientist within Great Ormond Street Hospital (GOSH) for almost 15 6

years. During this time I have completed Grade A Clinical Scientist training (1.1, 1.2), MRCPath 7

and FRCpath in Medical Microbiology by examination. Since embarking on a more research focus 8

post in 2009 I have undertaken a National Institute for Health Research (NIHR) Doctoral Fellowship 9

and Clinical Lectureship, as well as receiving over £20 million of grant funding. In addition to my 10

clinical and research responsibilities, I have been Trust Lead Healthcare Scientist at GOSH since 11

2017, holding professional leadership responsibility for over 700 staff and a remit for workforce, 12

research and education. In 2019, I was made an Honorary Fellow of the Academy for Healthcare 13

Science (1.3). 14

15

Team Structure 16

Working as Lead Healthcare Scientists I act as a professional lead to over 700 Healthcare Science 17

staff making up ~13% of the GOSH workforce. The Lead Healthcare Scientist role reports to the 18

Medical Director (medical) and Director of Education (nursing), and my Principal Clinical Scientist 19

role into the Clinical Lead for Microbiology and the Lead Nurse for Infection Prevention and Control 20

(2.1). 21

22

As Principal Clinical Scientist for Infection Prevention and Control I lead on Environmental 23

Infection Prevention and Control issues for a team of 5 to support patient safety (plus Estates and 24

Facilities and clinical laboratory teams) (2.1, 2.2, 8.1). This includes setting the strategic direction of 25

this work at multidisciplinary meetings consisting of nursing, medical, Healthcare Scientists, and 26

Estates and Facilities teams (2.1, 8.1). 27

28

Direct Reports (4.4): 29

Clinical team: 1*STP, 1*Biomedical Scientist Infection Prevention Control, 1 HSST trainee 30

Scientific team: 1*band 7 Clinical Scientist, 1*band 4 medical lab assistant in core molecular facility 31

Education team: 1*Practice Educator in Healthcare Science, 1 8B Lead Quality and Risk Manager 32

for Physiological Sciences 33

Research team (12.1): 2*current PhD students (C. difficile, environmental contamination), 2*masters 34

students (leadership, coagulase negative Staphylococcus aureus), 1*postdoctoral researcher 35

(antimicrobial nanoparticles), 2*NIHR Interns, and 1*NIHR Clinical Lecturer (C. difficile) 36

37

Research, Development and Innovation 38

39

I have been actively involved in research throughout my Clinical Scientist career. I currently have 40

27 publications (6 first author, 1 senior) with 195 citations, and an H-index of 8. Publications in 41

journals with impact factors ranging from 1.7 to 5.18 (2.6, 10.2, 11.2). Papers published have 42

directly influenced on the Trust and have fed into local policy (2.4). 43

44

Since 2010, I have successfully applied for 30 grants securing £21,004,997.83of funding from 45

funding councils, professional bodies and industry, 21 as primary applicant (10.2, 8.1, 12.1). This 46

had resulting in my managing a current budget of £3 million (3.2) with associated research 47

supervision responsibilities (see Team Structure) (4.4, 4.5, 5.3, 11.3). 48

49

As Trust Lead Healthcare Scientist, I am responsible for development an annual Trust wide research 50

strategy with linked training support (8.1, 10.1, 10.4, 12.1). Additionally, I am the ethics lead for 51

hospital-based research within the research group in order to support funding applications and 52

application of research within the clinical setting (3.2, 3.3, 7.2, 13.2) 53

54

My research work was acknowledged when I was shortlisted as a Finalist in the Advancing 55

Healthcare Awards (AHA) – NIHR Research Champion (2017) for application and transfer of 56

research include clinical settings to improve patient outcomes (6.1, 10.2, 10.3, 12.2). 57

58

Education and Workforce Development 59

60

Under my workforce and education remit I am managing an education budget of ~£60,000/year for 61

the GOSH Healthcare Science workforce (3.2), with responsibility to develop an annual Trust wide 62

education strategy to include accreditation support (4.1). As part of this work, I Co-Chair the 63

Healthcare Science Education Working Group (HSEWG), which has achieved: 64

Developed/commissioned £31,500.00 of courses since 2016 covering: mentorship, 65

presentation skills, patient communication, working at board level, paper and grant writing 66

(2.3, 4.1, 4.3, 4.6) 67

£31,500.00 allocated to support conference and external course attendance (4.4, 12.1) 68

Healthcare Science Education one day conferences (2017, 2018, 2019) co-funded by the 69

Royal Free and the GOSH HSEWG (Led by Dr Cloutman-Green) 325 attendees from across 70

the UK (4.6) 71

72

Additionally, under this remit I have worked with other Lead Healthcare Scientists across London to 73

establish the London Healthcare Science Education Collaborative. This project was established in 74

2018 and funded by HEE for (~£15,000.00) to work across the London STP footprint and provide 75

cross organisation training. Activities so far have included arranging 4*1 day training courses and 76

undertaking a London wide Healthcare Scientist survey with >350 responses, evaluating training 77

needs and training provision (2.2, 2.4, 4.8, 8.3, 14.2). 78

79

I also hold a number of teaching responsibilities linked to my clinical practice (see Education and 80

Workforce section in supporting information) including speaking at national and international 81

conferences and on Postgraduate training courses (2.6, 8.1, 4.5): 82

83

Clinical and Scientific Practice 84

85

My Clinical Scientist post requires the management of daily clinical queries, including response to 86

national alerts from Public Health England and Field Safety Notices (9.1, 15.2, 15.6). The clinical 87

role includes speaking to patients and families, making individual and Trust wide risk assessments, 88

dealing with complaints and freedom of information requests (2.3, 2.4, 3.5, 3.6, 5.5, 6.2, 7.2, 9.2, 89

15.1). It also includes following up and being involved with response to Serious Incidents and Major 90

Incidence Response (3.6, 6.3). 91

92

Within my Clinical Scientist role and that of Trust Lead Healthcare Scientist, I have developed 93

numerous business cases valued at over £500,000 including one to introduce IQIPS accreditation 94

across GOSH physiology departments (5.1, 5.2, 8.2, 14.1, 16.1). I have also undertaken considerable 95

laboratory service development, including verification, training and development of SOPs (3.4, 4.3, 96

4.6, 5.1, 5.2, 6.4, 7.1, 8.1, 9.3, 10.3, 10.4, 11.3, 12.3) (see Clinical and Scientific Practice supporting 97

information), including development of an environmental mycobacteria monitoring strategy (in 98

response to field safety notice) (15.5) 99

100

Based on research and publications I have developed clinical services and undertaken related audit, 101

education and monitoring including molecular environmental monitoring in response to viral cross 102

transmission detection as described under the Research, Development and Innovation (5.1, 5.2, 6.4, 103

8.2, 9.3, 11.2, 11.3, 12.2, 12.3). 104

105

I have been heavily involved in quality and accreditation work since I was a trainee. Currently this 106

work includes: Leading on Trust wide introduction of IQIPS and an International benchmarking 107

project for paediatric intensive care units (with Boston Children’s Hospital) (11.1, 3.1, 3.4, 13.1, 5.3, 108

5.5, 7.3, 8.2, 14.1, 15.7) 109

110

To support the dissemination of research, learning from incidents and best practice for environmental 111

IPC I established the Environmental Infection Control Network (EICN) in 2015, and holds annual 112

one day conferences to support networking for 50+ attendees (3.6, 4.6, 5.1, 8.3, 10.4). 113

114

Clinical Leadership 115

116

The combined posts I hold require leadership reporting into executive level and undertaking clinical 117

decisions that can impact Trust wide, such as closing wards or delaying the opening of buildings that 118

fail validation (see Team Structure) (9.1, 10.1). This leadership role includes inputting into 119

committee structures, both local and national, to develop guidelines/standards and services (15.1, 120

15.2, 15.3, 15.4,) 121

122

In 2016 I was awarded GOSH Exceptional Member of Staff award– awarded for examplifying the 123

GOSH Always Values (Always Helpful, Always Expert, Always One Team, Always Welcoming) 124

(1.3, 3.2. 15.1). In 2019 I was awarded the HEE Champion of the NHS Constitution award at the 125

national HEE HEAT awards for examplifying implementation of the NHS Constitution in everyday 126

practice. 127

128

Within GOSH I hold Membership/Chair 9 multi-disciplinary committees at with remits for 129

governance, patient safety, education (2.1, 4.1, 4.3, 4.4), clinical decision making setting Trust wide 130

strategy and introducing and evaluating changes in practice (2.1, 5.1, 6.3, 8.3). 131

In addition to my membership at GOSH I am a membership of 11 national committees responsible 132

for evaluating evidence, setting national guidelines and standards (scientific, clinical and education) 133

and ensuring professional representation (2.2, 4.2, 6.4, 8.3). These include being a Trustee for the 134

Society of Applied Microbiology with associated legal, financial and governance responsibilities 135

associated with being a registered director (3.2, 15.5), the Department of Education T-level panel 136

(4.2) and Chair of the EICN (2.2, 2.5, 4.6, 8.3). International committee membership includes acting 137

as a Country Ambassador for the Americal Society of Microbiology. 138

139

Patient and Public Engagement 140

141

In 2019 I received the CSO Partnering Patients and Citizens award for leading patient engagement 142

activities to support patient input into IPC intitiatives and development of education tools, as well as 143

to support open channels of patient feedback, working with over 100 patients in 2018 (2.2, 5.5, 8.2, 144

15.1): 145

IPC coffee mornings (2.3, 9.2) 146

Healthcare Science open days 147

Biomedical Research Centre open days 148

Remember, Remember activity for National Pathology Week 149

(https://www.eventbrite.com/e/remember-remember-tickets-51069401956#) 150

Clincal Research Stakeholder Group (2.5) 151

152

I am passionate about undertaking science communication activities with members of the public to 153

increase science literacy and raise awareness of clinical issues, such as antimicrobial resistance. In 154

2018 this involved communicating with over 900 members of the public (2.4, 2.5): 155

Reach Out for Healthcare Science (North London lead) – Awarded the Advancing Healthcare 156

Award in 2019 for Inspiring the Healthcare Science Workforce of the Future 157

Nosocomial (play raising awareness of Healthcare Scientists and their role in IPC) 158

(https://www.cptheatre.co.uk/blog/about-nosocomial-by-dr-elaine-cloutman-green/) 159

Science museum lates 160

161

Total word count: 1475 162

163

164

Supporting Information 165

166

Due to word limits, I have included further details to support my application below: 167

168

Posts held (with dates) 169

Lead Healthcare Scientist, Great Ormond Street Hospital (0.1 WTE) – 2017 to present 170

Principal Clinical Scientist in Infection Control Prevention and Control, Microbiology, 171

Virology and Infection Prevention and Control department, Great Ormond Street Hospital – 172

2016 to present: 173

June 2016 – May 2019 – NIHR Clinical Lectureship, NHS post partially funded by NIHR 174

2 month sabbatical at Boston Children’s Hospital (October and November 2017) 175

July 2010 – June 2015 – NIHR Doctoral Fellow, NHS post partially funded by NIHR 176

October 2009 – December 2016 – Clinical Scientist Infection Prevention and Control 177

October 2004 – September 2009 – Trainee Clinical Scientist 178

Honorary Lecturer, Department of Civil, Environmental and Geomatic Engineering, 179

University College London – 2016 to present 180

External Examiner, Staffordshire University – 2018 to present 181

182

Qualifications 183

Fellowship of the Higher Education Academy, 2017 (4.7) 184

Fellowship of the Royal College of Pathologists (RCPath) (Part 2 Medical Microbiology by 185

examination), 2016 (1.1) 186

PhD, University College London (UCL), ‘The Role of the Environment in Transmission of 187

HCAI’ January 2015 (8.1) 188

Post Graduate Certificate in Teaching and Learning in Higher and Professional Education, 189

Institute of Education, January 2016 (4.7) 190

Health Care Professionals Council registration 2009 (1.2) 191

Membership of the Royal College of Pathologists (Part 1 Medical Microbiology/Virology), 192

2007 193

Clinical Microbiology, MSc, University College London, 2006 194

Physics of Biological Interactions at Surfaces, MRes, Liverpool University, 2004 195

Zoology, BSc (Hons), Liverpool University, 2002 196

197

Esteem Indicators 198

Fellowship of the Academy of Healthcare Science, 2019 199

Fellowship of the Royal Society of Public Health, 2017 200

2019: Winner of the Health Education England HEAT awards – Champion of the NHS 201

Constitution 202

2019: Winner of the Chief Scientific Officer’s award - Healthcare Science Partnering Patients 203

and Citizens Award 204

2019: Winner at the Advancing Healthcare Awards – Inspiring Healthcare Scientists 205

Workforce of the Future for Reach Out for Healthcare Science 206

2018: Finalist in the Advancing Healthcare Awards – Inspiring Biomedical Scientists of the 207

Future 208

2017: Finalist in the Advancing Healthcare Awards – NIHR Research Champion 209

2016: Awarded Great Ormond Street Hospital Exceptional Member of Staff (GEMS) award 210

2016: Winner of the Chief Scientific Officer’s Healthcare Science Award for STEM 211

Engagement 212

2016: Winner of the Furness Prize for Science Communication (Royal College of 213

Pathologists) 214

2015: Mike Emmerson Young Investigator Award (Hospital Infection Society) 215

2015: Chief Scientific Officer’s 2015 award finalist – rising star 216

2015: Winner of the Voice of the Future competition (Royal Society of Biology) 217

218

Grants and other funding held (2010 – 2019 = £21,004,997.83) P = primary, C = co-applicant 219

2020 – 2024: REACH Lakanda Implementation Research for Mass Dosing of Azithromycin 220

in Mali. Funded by the Bill and Melinda Gates Foundation $20 million (£15,319,300). Co-221

applicant (UCL) C 222

2019 - 2022: Making the invisible visible: Modelling how ventilation and people movement 223

affect the deposition of pathogens in the hospital environment. Funded by the Engineering 224

and Physical Sciences Research Council for £90,297.00 C 225

2019 – 2021: Precision AMR, NIHR200652 - Funded by the National Institute of Health 226

Research for £3,305,144.00 C 227

2019 – 2022: Impact of Clostridium difficile on clinical outcomes in hospitalised infants with 228

diarrhoea (CD-COT) – Funded by the National Institute of Health Research for £589,412.00 229

C 230

2018: Nosocomial (outreach) – Funded by Healthcare Infection Society for £1000 P 231

2018: Nosocomial (outreach) – Funded by the Society of Applied Microbiology for £2800 P 232

2018: Remember, Remember (outreach) - Funded by the Royal College of Pathologists for 233

£500 P 234

2018: National Institute for Health Research ICA Internships *2 for £20,000.00 P 235

2017: Verification of Preparation Methods for Formula Feeds within Healthcare 236

Environments – Awarded by Sterifeed for £6075.00 C 237

2017: Great Ormond Street Hospital Clinical Sabbatical grant for £5026.00 P 238

2016 – 2017: Application of molecular typing in a routine clinical setting for the detection of 239

cross transmission events linked to Gram-negative bacteria – ACB Scholarship Prize awarded 240

by the Association of Clinical Biochemists and Laboratory Medicine for £7500.00 P 241

2016-2019: Antimicrobial filters for hospital air and water systems – Awarded by the 242

Engineering and Physical Sciences Research Council for £939,324.00 FEC C 243

2016 – 2017: Genomics Medicine module - Funded by Health Education England £1000.00 P 244

2016: Decontamination Study – Funded by Johnson and Johnson for £8397.00 P 245

2016 – 2019: The science of cleaning: applications, assessments and implications – CEGE 246

Impact Studentship for £106,114.00 C 247

2016 – 2019 Clinical Lectureship: Application of molecular typing in a routine clinical 248

setting for the detection of cross transmission events linked to Gram-negative bacteria – 249

Awarded by the National Institute for Health Research for £201,078.00 P 250

2015: Biomedical Research Centre Integrated Clinical Academic Fellowship Internship – 251

Awarded by the Great Ormond Street Hospital Biomedical Research Centre £5939.30 P 252

2015 – 2016: Whole Genome Sequencing To Investigation of Cross Transmission By 253

Enterobacteriaceae Within A Paediatric Hospital Setting - Mike Emmerson Young 254

Investigator Awarded by the Hospital Infection Society for £9000.00 P 255

2015: SHEA International Ambassador from the Society for Healthcare Epidemiology of 256

America (equiv. £2500.00) P 257

2014 – Decontamination Study – Funded by Steris for £5387.53 P 258

2014 - 2015 Research capacity building grant – Awarded by the Institute of Child Health for 259

£33,033.00 C 260

2014: Gina Pugliese scholarship from the Society for Healthcare Epidemiology of America 261

(equiv. £1000.00) P 262

2013: Mass Spectrometry: Applications to the Clinical Laboratory bursary (equiv. £1500.00) 263

P 264

2013: Society for General Microbiology bursary (equiv. £150.00) P 265

2012 – 2013: Development of Adenovirus detection and typing systems to investigate the 266

contribution of environmental contamination, cleaning and human behaviour in cross 267

transmission? – ACB Scholarship Prize awarded by the Association of Clinical Biochemists 268

for £2500.00 P 269

2012: Wellcome Trust advanced courses bursary (equiv. £1500.00) P 270

2012: Hospital Infection Society bursary (equiv. £1000.00) P 271

2011 – 2013: Protein detection trial in SSD – Awarded by the Department of Health for 272

£151,374.00 C 273

2010 - 2011: Development of Adenovirus detection and typing systems to investigate the 274

contribution of environmental contamination. cleaning and human behaviour in cross 275

transmission - Awarded by the Hospital Infection Society for £4800.00 P 276

2010 – 2015 CSO Fellowship: Reducing hospital acquired infections due to antibiotic 277

resistant Gram negative organisms – Awarded by the National Institute for Health Research 278

for £179,347.00 P 279

2010: Hospital Infection Society bursary (equiv. £1000.00) P 280

281

Publications (W = wrote, D = designed experiment, E = undertook experiment, R = reviewed 282

prior to publication); 283

1. Rawlinson S, Cloutman-Green E, Asadi F, Ciric L. Surface Sampling Within a Pediatric 284

Ward – How Multiple Factors Affect Cleaning Efficacy. AJIC (accepted November 2019) D, 285

R 286

2. Aljabr W, Armstrong S, Rickett NY, Pollakis G, Touzelet O, Cloutman-Green E, et al. High 287

Resolution Analysis of Respiratory Syncytial Virus Infection In Vivo. Viruses. 2019;11:926 288

R 289

3. Bankier, C, Matharu, R. K, Cheong, Y.K, Ren, G. G, Cloutman-Green, E, Ciric, L. 290

Synergistic Antibacterial Effects of Metallic Nanoparticle Combinations. October 2019 291

(accepted Nature Scientific Reports) W, R 292

4. Rawlinson S, Ciric L, Cloutman-Green E. How to carry out microbiological sampling of 293

healthcare environment surfaces? A review of current evidence. July 2017 (accepted JHI) W, 294

R 295

5. Cloutman-Green E, Barbosa VL, Jimenez D, Wong D, Dunn H, Needham B, Ciric L, 296

Hartley JC. Controlling Legionella pneumophilia in water systems at reduced hot water 297

temperatures with copper and silver ionization. November 2018 (accepted to AJIC) W 298

6. Farrer R, Ford CB, Rhodes J, Delorey T, May R, Fisher MC, Cloutman-Green E, Balloux F, 299

Cuomo CA. Transcriptional heterogeneity of Cryptococcus gattii VGII compared with non-300

VGII lineages underpins key pathogenicity pathways. August 2018 DOI: 10.1101/396796 301

(accepted to mSphere) R 302

7. Houldcroft CJ, Roy S, Morfopoulou S, Margetts BK, Depledge DP, Cudini J, Shah D, Brown 303

JR, Yara Romero E, Williams R, Cloutman-Green E, Rao K4, Standing JF, Hartley J, 304

Breuer J. Use of Whole-genome Sequencing of Adenovirus in Immunocompromised 305

Paediatric Patients to Identify Nosocomial Transmission and Mixed-genotype Infection. J 306

Infect Dis. 2018 Jun 4. doi: 10.1093/infdis/jiy323. E, R 307

8. Bankier C, Cheong Y, Mahalingam S, Edirisinghe M, Ren G, Cloutman-Green E, Ciric L. 308

A comparison of methods to assess the antimicrobial activity of nanoparticle combinations on 309

bacterial cells. PLoS One. 2018 Feb 1;13(2):e0192093. D, R 310

9. Cheong YK, Calvo-Castro J, Ciric L, Edirisinghe M, Cloutman-Green E, Illangakoon UE, 311

Kang Q, Mahalingam S, Matharu RK, Wilson RM, Ren G. Characterisation of the Chemical 312

Composition and Structural Features of Novel Antimicrobial Nanoparticles. Nanomaterials 313

(Basel). 2017 Jun 23;7(7). R 314

10. Eranka Illangakoon, Suntharavathanan Mahalingam, Katherine Wang, Y. K.Cheong, Melisa 315

Canales, Guogang Ren, Elaine Cloutman-Green, Mohan Edirisinghe, Lena Ciric. Gyrospun 316

antimicrobial nanoparticle loaded fibrous polymeric filters. Materials Science and 317

Engineering: C. Volume 74, 1 May 2017, Pages 315–324. R 318

11. Cloutman-Green E, Canales M, Pankhurst L, Evenor T, Malone D, Klein N, Ciric L, 319

Hartley JC. Development and implementation of a cleaning standard algorithm to monitor the 320

efficiency of terminal cleaning in removing Adenovirus within a paediatric hematopoietic 321

stem cell transplantation unit. Am J Infect Control. 2015 Sep; 43(9): 997-999. W, D, E 322

12. Cloutman-Green E, Canales M, Qizhi Zhou, Ciric L, Hartley JC, McDonnell G. 323

Biochemical and microbial contamination of surgical devices: A quantitative analysis. Am J 324

Infect Control. 2015 Jun;43(6):659-61. W, D, E 325

13. Patel P, Tuke P, Tettmar K, Cloutman-Green E, Hartley J, Klein N, Veys P, Tedder R. 326

Adenovirus and Epstein Barr virus infections in paediatric recipients post bone marrow 327

transplant: possible transfusion transmitted infections? Vox Sanguinis. 2015 Jul;109(1):95-7. 328

E, R 329

14. Cloutman-Green E, Pankhurst L, Canales M, D’Arcy N, JC Hartley. Routine Monitoring of 330

Adenovirus and Norovirus within the Healthcare Environment. Am J Infect Control. 2014 331

Nov;42(11):1229-32. W,D 332

15. Cloutman-Green E, D’Arcy N, Spratt DA, Hartley JC and Klein N. How Clean is Clean – 333

Is a New Microbiological Standard Required? Am J Infect Control. 2014 Sep;42(9):1002-3. 334

W, D, E 335

16. D’Arcy N, Cloutman-Green E, Spratt DA, Hartley JC and Klein N. Environmental viral 336

contamination in a paediatric hospital: implications for infection control. Am J Infect 337

Control. 2014 Aug;42(8):856-60. D, R 338

17. Cloutman-Green E, Kalaycioglu O, Wojani H, Hartley JC, Guillas S, Malone D, Gant V, 339

Grey C, Klein N. The important role of sink location in hand washing compliance and 340

microbial sink contamination. Am J Infect Control. 2014. Vol. 42, Issue 5, Pages 554-341

555 W, D, E 342

18. D’Arcy N, Cloutman-Green E, Lai K, Margaritis D, Klein N, Spratt DA. Potential exposure 343

of children to environmental microorganisms in indoor healthcare and educational settings. 344

Indoor and Built Environment, May 2014; vol. 23, 3: pp. 467-473 R 345

19. Gaudart J, Cloutman-Green E, Guillas S, D'Arcy N, Hartley JC, Gant V, Klein N. 346

Healthcare environments and spatial variability of healthcare associated infection risk: cross-347

sectional surveys. PLoS One. 2013 Sep 19;8(9):e76249. D, E, R 348

20. Voets GM, Leverstein-van Hall MA, Kolbe-Busch S, van der Zande A, Church D, Kaase M, 349

Grisold A, Upton M, Cloutman-Green E, Cantón R, Friedrich AW, Fluit AC; The 350

DiversiLab Study Group. International Multicenter Evaluation of the DiversiLab Bacterial 351

Typing System for Escherichia coli and Klebsiella spp. J Clin Microbiol. 2013 352

Dec;51(12):3944-9 E, R 353

21. Nayuni NK, Cloutman-Green E, Hollis M, Hartley J, Martin S, Perrett D. Critical 354

evaluation of ninhydrin for monitoring surgical instrument decontamination. J Hosp Infect. 355

2013 Jun;84(2):97-102 R 356

22. Wojgani H, Kehsa C, Cloutman-Green E, Gray C, Gant V, Klein N. Hospital door handle 357

design and their contamination with bacteria: a real life observational study. Are we pulling 358

against closed doors? PLoS One. 2012;7(10):e40171. E, R 359

23. Moore G, Ali S, Cloutman-Green EA, Bradley CR, Wilkinson MA, Hartley JC, Fraise 360

AP, Wilson AP. Use of UV-C radiation to disinfect non-critical patient care items: a 361

laboratory assessment of the Nanoclave Cabinet. BMC Infect Dis. 2012 Aug 3;12:174 D, E, 362

R 363

24. Pankhurst, L. J., Lai, K. M., Cloutman-Green, E. A. and Hartley, J. C. Can clean-room 364

particle counters be used as an infection control tool in hospital operating theatres? Indoor 365

and Built Environment, June 2012; vol. 21, 3: pp. 381-391 D, R 366

25. Mark Bishay, Giuseppe Retrosi, Venetia Horn, Elaine Cloutman-Green, Kathryn Harris, 367

Paolo De Coppi, Nigel Klein, Simon Eaton, Agostino Pierro. Septicaemia Due To Enteric 368

Organisms Is A Later Event In Surgical Infants Requiring Parenteral Nutrition. European 369

Journal of Paediatric Surgery. 2012 Feb;22(1):50-3 R 370

26. Mark Bishay, Giuseppe Retrosi, Venetia Horn, Elaine Cloutman-Green, Kathryn Harris, 371

Paolo De Coppi, Nigel Klein, Simon Eaton, Agostino Pierro. Chlorhexidine antisepsis 372

significantly reduces the incidence of sepsis and septicemia during parenteral nutrition in 373

surgical infants. Journal of Pediatric Surgery (2011) 46, 1064–1069 R 374

27. Harris KA, Turner P, Green EA, Hartley JC. A duplex real-time PCR assay for the detection, 375

and determination of penicillin susceptibility, of Streptococcus pneumoniae in clinical 376

samples. J Clin Microbiol. 2008 Aug;46(8):2751-8 E, R 377

378

379

380

Clinical and Scientific Practice 381

382

Daily clinical responsibilities include (5.4, 5.5, 8.1, 9.1, 14.2): 383

Ward rounds (6.2) 384

Review of positive results (6.1) 385

Managing clinical enquiries and providing patient management advice (6.2) 386

Attendance at Trust wide committees to support strategic responses, clinical governance and 387

service planning (see Clinical Leadership) (6.3) 388

Outbreak meetings and review (6.2) 389

Incident investigation, reporting and review (3.5, 6.4) 390

391

Business cases undertaken (5.1, 5.2, 8.2, 14.1, 16.1) P = primary, C = co-applicant: 392

Introduction of IQIPS accreditation across physiology services at GOSH £214,076.00 P 393

Introduction of MALDI-ToF to bacteriology services £115,000.00 (5.2, 10.3) P 394

Introduction of whole genome sequencing for IPC (~£50,000.00) (6.4, 9.3, 10.3) C 395

Modification of blood culture machines to support service development (9.3) C 396

Environmental monitoring service support, bringing in-house (cost neutral) P 397

398

Laboratory service development, including verification, training and development of SOPs (3.4, 4.3, 399

4.6, 5.1, 5.2, 6.4, 7.1, 8.1, 9.3, 10.3, 10.4, 11.3, 12.2, 12.3): 400

Development of an environmental mycobacteria monitoring strategy (in response to field 401

safety notice) (15.5) 402

Alteration of Clostridium difficile testing and workflow in response to national guidelines 403

(requirement for negatives in <48 hours) (15.6) 404

Introduction of new Carbapenem Resistant Enterobacteriaceae workflow to support 405

compliance with Public Health England guidance and reduce negative patient impact (15.6) 406

Rapid MALDI-ToF identification of positive blood cultures linked to Sepsis 6 pathway 407

408

Clinical service development - audit, education and monitoring (5.1, 5.2, 6.4, 8.2, 9.3, 11.3, 12.3) 409

Clinical audit and linked education improvement of surface cleaning within intensive care 410

wards (11.1) 411

Introduction of hydrogen peroxide vapour cycles to improve safety during infection cleaning 412

response 413

Molecular environmental monitoring in response to viral cross transmission detection 414

Environmental monitoring algorithms in response to bacterial cross transmission detection 415

416

Quality and Accreditation (5.3, 5.5, 8.2, 14.1, 15.7): 417

Pre analytical sample pathways project to reduce requirements for sample repeats 418

Leading on Trust wide introduction of IQIPS accreditation for physiology services (3.1, 3.4, 419

13.1) 420

Environmental service and clinical training SOPS for ISO 15189 compliance (3.1, 3.3, 3.4, 421

13.1) 422

International benchmarking project for paediatric intensive care units (with Boston Children’s 423

Hospital) (11.1) 424

International benchmarking project on paediatric IPC (with Boston Children’s Hospital) 425

(11.1) 426

427

428

429

Committee Membership (Clinical Leadership) 430

431

Committee membership at Great Ormond Street Hospital (current) (5.4, 15.2): 432

Infection Prevention and Control committee (2.1, 5.1, 6.3) 433

Ventilation committee (2.1, 5.1, 6.3) 434

Water Management group (2.1, 5.1, 6.3) 435

Water Safety group (2.1, 5.1, 6.3) 436

Decontamination group (2.1, 5.1, 6.3) 437

HSEWG (Chair) (4.3, 4.4) 438

Point of Care Testing committee (2.1, 5.1, 6.3) 439

Education board (2.1, 4.1) 440

441

Committee membership at regional level (current) (5.4, 14.2, 15.3, 15.4): 442

Member of the London Scientific Diagnostic Network (2.2) 443

London Healthcare Science Education Collaborative (Lead) (2.2, 4.8, 8.3) 444

London Clinical Senate Council 445

446

Committee membership at national level (current) (5.4, 15.3, 15.4): 447

NIHR Healthcare Science Training Advocate 448

NIHR CRN Infection Speciality Group Diagnostic Lead 449

Member of the Executive Committee for the Society of Applied Microbiology (3.2) 450

Member of the Water Management Society Water Safety Forum 451

Member of the Healthcare Infection Society (HIS) Working Group on Water Management 452

(6.4) 453

UK AMR Diagnostic Programme Board (6.4) 454

Member of the HIS Scientific Development Committee 455

Member of the Chief Scientific Officer’s (CSO) Lead Healthcare Scientist Network (2.2) 456

Member of BSI water safety plan committee (6.4) 457

Member of the STP Microbiology Specialty Curriculum Review Panel (4.2) 458

Member of Microbiology Professionals Committee, Association of Clinical Biochemists and 459

Laboratory Medicine) 460

Chair of the EICN (2.2, 2.5, 4.6, 8.3) 461

Member of Microbiology OSFA examination group for the National School for Healthcare 462

Sciences (4.2) 463

Committee membership at international level (5.4, 15.3, 15.4): 464

2017 – 2020: Country Ambassador for the Americal Society of Microbiology 465

2016 onwards: EBMT Infectious Diseases Working Party (IDWP) working group for the 466

development of “Guidelines on protective environment in HSCT setting (6.4) 467

2015: Society of Healthcare Epidemiology of America International Ambassador 468

469

470

471

472

473

474

475

476

477

478

479

480

481

482

483

484

485

486

487

488

489

490

491

492

493

494

495

496

AHCS Standard of Proficiency Location of Evidence

Professional Practice

Standard 1 – Practise with the professionalism expected of a Consultant Clinical Scientist

1.1 Demonstrate an understanding of Good

Scientific Practice at Consultant Clinical

Scientist level

Line no:

6, 125, 186

1.2 Comply with the codes of conduct of the

Health and Care Professions Council; and the

Academy for Healthcare Science

Line no:

6, 191

1.3 Ensure that conduct at all times justifies

the trust of patients and colleagues and

maintains the public’s trust in the scientific

profession

Line no:

14

Standard 2 – Ensure professionalism in working with peers and with service users

2.1 Lead a team to work effectively with

senior colleagues in cross professional settings

and across organisational boundaries

Line no:

21, 25, 27, 130, 433, 434, 435, 436, 437,

439, 440

2.2 Lead a team to work in partnership with

colleagues and other organisations in the best

interest of patients, local communities and the

wider population

Line no:

25, 78, 134, 137, 144, 443, 444, 456, 461

2.3 Create a culture of openness with patients,

their families, carers or representatives and

colleagues, including if anything goes wrong;

welcoming and listening to feedback and

addressing concerns promptly

Line no:

67, 89, 146

2.4 Communicate complex clinical scientific

and technical information in a wide range of

settings and formats, including to patients and

the public

Line no:

43, 78, 89, 155

2.5 Liaise with peers, clinical users of the

service, patients and the public on all aspects of

service delivery to ensure that the service is fit

for purpose

Line no:

137, 151, 155, 461

2.6 Communicate research, innovation and

development findings as appropriate, including

peer reviewed journals and at national and

international conferences

Line no:

42, 82

Standard 3 – Ensure professionalism in areas of governance and service accreditation

3.1 Assume overall accountability for ensuring

compliance with the governance and risk

management requirements for a broad scientific

service

Line no:

108, 419, 421

3.2 Demonstrate a high level of

professionalism in personal performance

including confidentiality, ethical standards and

financial probity

Line no:

47, 53, 62, 125, 136, 450

3.3 Ensure effective clinical governance of

scientific services and personal practice

according to their organisation’s clinical

governance policies

Line no:

53, 421

3.4 Ensure the service meets service

accreditation standards

Line no:

96, 108, 399, 419, 421

3.5 Ensure the formal reporting and recording

of any adverse incidents is in line with

organisational policy

Line no:

89, 390

3.6 Investigate adverse events and complaints

ensuring that lessons learnt are shared

appropriately and that systems are put in place

to minimize the risk or recurrence

Line no:

89, 91, 113

Standard 4 – Direct the education and training of others

4.1 Develop a strategic approach to the

provision of appropriate training programmes

for the breadth of the scientific workforce and

contribute to training other groups of staff

within healthcare

Line no:

63, 67, 130

4.2 Advise on national training requirements

and curriculum for the breadth of training in the

scientific workforce

Line no:

134, 137, 458, 463

4.3 Evaluate and make provision for the

teaching and training requirements of scientific

staff, professional colleagues and users of the

service

Line no:

67, 96, 130, 399, 438

4.4 Provide scientific staff with appropriate

professional and personal development

opportunities through robust appraisal

processes, with access to appropriate training for

Line no:

29, 48, 68, 130, 438

their jobs and the line management support

needed to succeed

4.5 Participate in clinical scientific and

technical teaching, training and assessment of

peers, undergraduates, post-graduates and other

healthcare professionals within relevant

scientific areas of practice using effective

methods of learner-centred feedback

Line no:

48, 82

4.6 Develop and introduce teaching

programmes in own area of specialist practice

and continually evaluate and improve teaching

and assessment activities using critical reflection

Line no:

67, 71, 97, 113, 137, 400, 461

4.7 Demonstrate personal training, skills and

qualifications (where relevant) to provide high

quality teaching, training, assessment and

feedback

Line no:

184, 190

4.8 Evaluate the quality of teaching and

training provided and make recommendations

for improvement

Line no:

78, 444

Scientific Practice

Standard 5 – Lead scientific services

5.1 Assess the demand and specification for

evolving scientific services with users, clinical

colleagues and other relevant stakeholders

Line no:

95, 97, 103, 113, 392, 400, 409, 433, 434,

435, 436, 437, 439, 440

5.2 Evaluate the scientific literature and other

scientific sources and work with others to

develop scientific and business cases for service

improvement

Line no:

95, 97, 103, 392, 394, 400, 409

5.3 Lead a clinical scientific department

offering a broad range of services and creating a

culture of continuous improvement and

innovation

Line no:

48, 108, 417

5.4 Provide a high level of scientific expertise

to complex problems in own area of specialist

practice

Line no:

383, 432, 442, 447, 464

5.5 Ensure that clinical scientific services are

delivered with a commitment to excellent

quality, safety, confidentiality, accountability,

reliability, communication and professional and

managerial integrity

Line no:

89, 108, 144, 383, 417

Standard 6 – Direct scientific validation and evaluation

6.1 Ensure the clinical scientific validation of

analytical results ensuring that complex

investigations are accurately and critically

evaluated

Line no:

57, 385

6.2 Provide consultant level clinical scientific

advice, including interpretation of investigations

and their outcomes, therapies and their

implications for patient care and management,

and recommendations for additional or more

complex investigations

Line no:

89, 384, 386, 389

6.3 Provide scientific advice on legislative

compliance in own specialist area of practice

Line no:

91, 388, 433, 434, 435, 436, 437, 439, 440

6.4 Bring critical analysis to the practice of the

clinical scientific specialism, ensuring that

regular review of research and evidence is

undertaken so that adaptation to practice can be

made in a timely and cost- effective manner

Line no:

97, 103, 134, 390, 395, 400, 409, 453, 454,

457, 467

Standard 7 – Assure safety in the scientific setting

7.1 Ensure delivery of the highest standards of

health and safety in the working environment

Line no:

97, 400

7.2 Introduce and critically evaluate measures

to identify, actively manage and reduce risk to

patients

Line no:

53, 89

7.3 Ensure services are delivered in clean and

safe environments that are fit for purpose, based

on national best practice

Line no:

25, 109

497

Clinical Practice

Standard 8 – Ensure clinical relevance of

scientific services provided

8.1 Ensure highly developed and advanced

clinical scientific expertise, advice and

interpretation to the multi-professional clinical

team and to patients, undertaking scientific

responsibilities at a level of accountability

similar to that of consultant doctors, but with the

recognition that the overall clinical

responsibility for patients resides with an

accountable medical consultant or General

Practitioner

Line no:

25, 27, 46, 51, 82, 97, 188, 383, 400

8.2 Lead high quality patient focused clinical

scientific services that promote excellent patient

outcomes, support patient involvement and

engagement and continually seek to improve the

safety and quality of NHS clinical scientific

services

Line no:

95, 104, 108, 144, 392, 409, 417

8.3 Collaborate with colleagues across

organisational boundaries to develop, promote

and participate in a multi-professional approach

to high quality patient care and management

Line no:

78, 113, 130, 134, 137, 444, 461

Standard 9 – Deliver effective clinical

services

9.1 Play a direct role in the management of

complex patients, as part of a multi-professional

team, including assessment of the patient’s

relevant history, developing an investigation

strategy, interpreting results and agreeing a

management and treatment plan in partnership

with the patient, medical staff and the rest of the

multi professional team

Line no:

87, 119, 383

9.2 In appropriate circumstances and within

the context of particular and defined clinical

circumstances, impart scientific results to and

discuss with patients or their families,

investigations, risks and outcomes that may be

highly sensitive, emotive or have serious

prognostic implications, recognising that the

responsibility for the overall care of the patient

Line no:

89, 146

rests with the accountable medical consultant or

General Practitioner

9.3 Respond positively to and promote new

developments that enable patients to have

greater access to information about their care

Line no:

97, 104, 395, 396, 400, 409

Research, Development and Innovation

Standard 10 – Lead research, development and innovation in clinical priority areas

10.1 Contribute at the highest level to the

strategic development and direction of the

organisation so that the added value of clinical

science services and their impact on patient care

is fully realised

Line no:

51, 119

10.2 Lead and shape the application of

advances in science, technology, research,

innovation, especially in the area of

genomics and personalised / precision

medicine, and education to support

continuous improvement of patient outcomes

Line no:

42, 46, 57

10.3 Through the initiation and translation of

cutting edge scientific research and education,

bring strategic direction, innovation and

continuous improvement into practice

Line no:

57, 97, 394, 395, 400

10.4 Promote safe and high quality care by

ensuring that cutting edge research and

evidence based practice is at the vanguard of

clinical scientific services

Line no:

51, 97, 113

Standard 11 – Evaluate research, development and innovation outcomes to improve

scientific service provision

11.1 Develop and apply a strategy to optimise

the impact of clinical audit to deliver outcome

focused quality improvement programmes

Line no:

108, 411, 424, 426

11.2 Continually improve the quality of

clinical scientific services by directing and

planning the introduction, evaluation and

Line no:

42, 104

application of improved scientific and

operational procedures

11.3 Evaluate published research and

innovation for patient benefit and make

recommendations for improvements in the

quality of services and patient outcomes based

on these

Line no:

48, 97, 104, 400

Standard 12 – Promote a culture of

innovation

12.1 Generate a culture that values and

supports innovation and quality by promoting

and stimulating research and innovation both

within the service and across service boundaries

Line no:

34, 46, 51, 68

12.2 Initiate and direct research and innovation

programmes to completion, evaluate outcomes

and amend service provision as appropriate

Line no:

57, 104, 400

12.3 Identify opportunities to innovate and

create a culture where innovation flourishes

Line no:

97, 104, 400, 409

Standard 13 – Assure research governance

13.1 Design and lead a strategy to achieve and

/ or maintain service accreditation

Line no:

108, 420, 422

13.2 Ensure compliance with the NHS ethical

and research governance framework

Line no:

53

Clinical Leadership

Standard 14 – Ensure strategic leadership

14.1 Lead strategic service improvement

across a broad service, demonstrating an ability

to successfully initiate, manage and sustain

change aimed at improving patient outcomes

Line no:

95, 109, 392, 417

14.2 Lead and motivate clinical scientific staff

to ensure effective delivery and achievement of

agreed service objectives in a changing

healthcare environment

Line no:

78, 383, 442

Standard 15 – Ensure clinical scientific leadership

15.1 Ensure scientific services reflect the needs

and preferences of patients, their families, carers

as well as the public health requirements of the

populations they serve

Line no:

89, 120, 125, 145

15.2 Direct the operation of a broad service to

ensure compliance with local, national and

internationally accepted standards and

guidelines

Line no:

87, 120, 432

15.3 Participate in appropriate local regional,

national and international scientific groups

Line no:

120, 442, 447, 464

15.4 Play a leading role in appropriate local,

regional, national and international clinical

scientific groups

Line no:

120442, 447, 464

15.5 Contribute to the activities of national

professional bodies and the formulation of

national/international guidelines on clinical,

scientific, and safety issues relating to services

Line no:

99, 136, 402, 442, 447, 464

15.6 Ensure that scientific services are

delivered in accordance with recommendations

for national screening programmes, diagnostic

practice and health and safety guidance

Line no:

87, 404, 406

15.7 Ensure that engagement in the

commissioning of scientific services is carried

out with full compliance to good practice

Line no:

109, 417

Standard 16 – Assure effective management

of resources

16.1 Ensure that staff and non-staff resources

are assessed and deployed to obtain the required

high quality whilst offering best value for

money

Line no:

95, 392

498

499